Optimizing (O) Rifapentine-based (RI) Regimen and Shortening (EN) the Treatment of Drug-susceptible Tuberculosis (T) (ORIENT) Using an Adaptive Seamless Design: Study Protocol of a Multicenter Randomized Controlled Trial

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 May 9

PMID 37158831

Authors

Zhen Feng

Yan Miao

Ying Peng

Feng Sun

Yilin Zhang

Rong Li

Shijia Ge

Xinchang Chen

Lingyun Song

Yang Li

Xiaomeng Wang

Wenhong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Standard treatment for drug-susceptible tuberculosis (DS-TB) includes a multidrug regimen requiring at least 6 months of treatment, and this lengthy treatment easily leads to poor adherence. There is an urgent need to simplify and shorten treatment regimens to reduce interruption and adverse event rates, improve compliance, and reduce costs.

Methods: ORIENT is a multicenter, randomized controlled, open-label, phase II/III, non-inferiority trial involving DS-TB patients to evaluate the safety and efficacy of short-term regimens compared with the standardized six-month treatment regimen. In stage 1, corresponding to a phase II trial, a total of 400 patients are randomly divided into four arms, stratified by site and the presence of lung cavitation. Investigational arms include 3 short-term regimens with rifapentine 10 mg/kg, 15 mg/kg, and 20 mg/kg, while the control arm uses the standardized six-month treatment regimen. A combination of rifapentine, isoniazid, pyrazinamide, and moxifloxacin is administered for 17 or 26 weeks in rifapentine arms, while a 26-week regimen containing rifampicin, isoniazid, pyrazinamide, and ethambutol is applied in the control arm. After the safety and preliminary effectiveness analysis of patients in stage 1, the control arm and the investigational arm meeting the conditions will enter into stage 2, which is equivalent to a phase III trial and will be expanded to recruit DS-TB patients. If all investigational arms do not meet the safety conditions, stage 2 will be canceled. In stage 1, the primary safety endpoint is permanent regimen discontinuation at 8 weeks after the first dose. The primary efficacy endpoint is the proportion of favorable outcomes at 78 weeks after the first dose for both two stages.

Discussion: This trial will contribute to the optimal dose of rifapentine in the Chinese population and suggest the feasibility of the short-course treatment regimen containing high-dose rifapentine and moxifloxacin for DS-TB.

Trial Registration: The trial has been registered on ClinicalTrials.gov on 28 May 2022 with the identifier NCT05401071.

References

Fox W, Ellard G, Mitchison D . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999; 3(10 Suppl 2):S231-79. View

Pang Y, Zhang Z, Wang Y, Wang S, Song Y, Zhao B . Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother. 2016; 61(2). PMC: 5278687. DOI: 10.1128/AAC.02170-16. View

. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. Tubercle. 1982; 63(2):89-98. DOI: 10.1016/s0041-3879(82)80044-5. View

Alipanah N, Jarlsberg L, Miller C, Linh N, Falzon D, Jaramillo E . Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018; 15(7):e1002595. PMC: 6029765. DOI: 10.1371/journal.pmed.1002595. View

Savic R, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W . Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014; 58(6):3035-42. PMC: 4068478. DOI: 10.1128/AAC.01918-13. View

Lee A, Xie Y, Barry C, Chen R . Current and future treatments for tuberculosis. BMJ. 2020; 368:m216. DOI: 10.1136/bmj.m216. View

Merle C, Fielding K, Sow O, Gninafon M, Lo M, Mthiyane T . A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014; 371(17):1588-98. DOI: 10.1056/NEJMoa1315817. View

Gillespie S, Crook A, McHugh T, Mendel C, Meredith S, Murray S . Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 371(17):1577-87. PMC: 4277680. DOI: 10.1056/NEJMoa1407426. View

Temple M, Nahata M . Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother. 1999; 33(11):1203-10. DOI: 10.1345/aph.18450. View

10.

Chen R, Via L, Dodd L, Walzl G, Malherbe S, Loxton A . Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Res. 2018; 1:9. PMC: 5841574. DOI: 10.12688/gatesopenres.12750.1. View

11.

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho A . Tuberculosis elimination: where are we now?. Eur Respir Rev. 2018; 27(148). PMC: 9488456. DOI: 10.1183/16000617.0035-2018. View

12.

Diacon A, Patientia R, Venter A, Van Helden P, Smith P, McIlleron H . Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007; 51(8):2994-6. PMC: 1932511. DOI: 10.1128/AAC.01474-06. View

13.

Dooley K, Savic R, Park J, Cramer Y, Hafner R, Hogg E . Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015; 59(6):3399-405. PMC: 4432148. DOI: 10.1128/AAC.05128-14. View

14.

Ginsburg A, Hooper N, Parrish N, Dooley K, Dorman S, Booth J . Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003; 37(11):1448-52. DOI: 10.1086/379328. View

15.

Dorman S, Nahid P, Kurbatova E, Phillips P, Bryant K, Dooley K . Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021; 384(18):1705-1718. PMC: 8282329. DOI: 10.1056/NEJMoa2033400. View

16.

Jindani A, Harrison T, Nunn A, Phillips P, Churchyard G, Charalambous S . High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 371(17):1599-608. PMC: 4233406. DOI: 10.1056/NEJMoa1314210. View

17.

Jarvis B, Lamb H . Rifapentine. Drugs. 1998; 56(4):607-16; discussion 617. DOI: 10.2165/00003495-199856040-00008. View

18.

Svensson E, Svensson R, Te Brake L, Boeree M, Heinrich N, Konsten S . The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018; 67(1):34-41. PMC: 6005123. DOI: 10.1093/cid/ciy026. View

19.

Decroo T, de Jong B, Piubello A, Lynen L, Van Deun A . Tuberculosis treatment: one-shot approach or cascade of regimens?. Lancet Respir Med. 2020; 8(2):e4-e5. DOI: 10.1016/S2213-2600(19)30473-4. View

20.

Dorman S, Savic R, Goldberg S, Stout J, Schluger N, Muzanyi G . Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2014; 191(3):333-43. PMC: 5447287. DOI: 10.1164/rccm.201410-1843OC. View